HPV vaccine in healthy donors could help fight cancer

NCT ID NCT06508138

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests an HPV vaccine series in healthy relatives of patients with advanced HPV-related cancer. The goal is to generate HPV-specific white blood cells that can be collected and used in a bone marrow transplant or donor lymphocyte infusion for the patient. The study focuses on safety and immune response in the donors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HPV vaccine series (pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV vaccinia virus)
What this could lead to
If successful, this approach could help treat patients with advanced HPV-related cancers by using vaccinated donor immune cells.
What could go wrong
This is a very early phase 1 trial with only 24 healthy donors, so safety and immune response are still being tested. The linked recipient trial is also early, and the treatment may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV 16 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.